API CAS 154598-52-4 Efavirenz Pharmaceutical Intermediate Efavirenz Medicine Powder Efavirenz

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Model NO.: Dsung-Efavirenz
• Product Name: Efavirenz
• Name: Efavirenz Powder
• Appearance: White to off-White Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical Intermediate
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 154598-52-4
• Mf: C14h9clf3no2
• MW: 315.676
• Melting Point: 139-141 C
• Boiling Point: 340.6 C at 760 Mmhg
• Density: 1.53
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 10kg/Month

Product Description

API CAS 154598-52-4 Efavirenz Pharmaceutical Intermediate Efavirenz Medicine Powder Efavirenz

 

Product Description

Product Details

Product Name	Efavirenz
CAS No.	154598-52-4
MF	C14H9ClF3NO2
MW	315.676
Appearance and shape	White to off-white powder

Efavirenz D5 (Sustiva)84 is also mandated for use with at leasttwo other antiretroviral agents. The compound is morethan 99% protein bound, and CSF concentrations exceedthe free fraction in the serum. Metabolism occurs in theliver. The half-life of a single dose of Efavirenz D5 is 52 to 76hours, and 40 to 55 after multiple doses (the drug inducesits own metabolism). Peak concentration is achieved in 3to 8 hours. Elimination is 14% to 34% in urine (as metabolites)and 16% to 41% in feces (primarily as Efavirenz D5).The oral dosage form is supplied as a capsule.

Application & Function

Function of Efavirenz
Efavirenz is one of the most commonly prescribed antiretroviral medications in the world. Several large randomized, controlled trials[RCTs] have demonstrated the superior ability of efavirenz to suppress the HIV virus when used as part of a 3-drug cocktail[2]. The introduction of Atripla in 2006 combined efavirenz and two other agents into a single pill, once-daily formulation. This formulation was more convenient and better tolerated than alternatives, and thus resulted in improved adherence to antiretroviral medications[3]. However, neuropsychiatric side effects associated with efavirenz have been reported to occur in 40-50% of patients and represent one of the limiting factors of this regime
Application of Efavirenz
For use in combination treatment of HIV infection (AIDS)

Specification